From immunome to vaccine: Epitope mapping and vaccine design tools

Novartis Foundation Symposium

Volumn 254, Issue , 2003, Pages 57-76

  De Groot, Anne S ^a,b   Martin, William ^b   Margalit, ^c  

^a BROWN UNIVERSITY   (United States)

^b EpiVax Inc   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; VACCINE;

ANIMAL; BIOLOGY; COMPUTER AIDED DESIGN; DRUG DESIGN; EPITOPE MAPPING; GENETICS; GENOMICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOUSE; REVIEW;

ALLERGY AND IMMUNOLOGY; ANIMALS; ANTIGENS; COMPUTATIONAL BIOLOGY; COMPUTER-AIDED DESIGN; DRUG DESIGN; EPITOPE MAPPING; GENOMICS; HUMANS; MICE; VACCINES;

EID: 1342310859     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (51)

1. Altuvia Y, Schueler O, Margalit H 1995 Ranking potential binding peptides to MHC molecules by a computational threading approach. J Mol Biol 249:244-250
2. An LL, Whitton JL 1997 A multivalent minigene vaccine, containing B cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen. J Virology 71:2292-2302
3. An LL, Rodriguez F, Harkins S, Zhang J, Whitton JL 2000 Quantitative and qualitative analyses of the immune responses induced by a multivalent minigene DNA vaccine. Vaccine 18:2132-2141
4. Behr MA 2001 Correlation between BCG genomics and protective efficacy. Scand J Infect Dis 33:249-252
5. Bende S, Johnston MI 2000 Immunisation. Update: search for an Aids vaccine. AIDS Read 10:526-538
6. Brusic V, Rudy G, Harrison LC 1994 MHCPEP: a database of MHC-binding peptides. Nucleic Acids Res 22:3663-3665
7. Charo J, Sundback M, Geluk A, Ottenhoff T, Kiessling R 2001 DNA immunization of HLA transgenic mice with a plasmid expressing mycobacterial heat shock protein 65 results in HLA class I- and II-restricted T cell responses that can be augmented by cytokines. Hum Gene Ther 12:1797-1804
8. Cummings CA, Relman DA 2000 Using DNA microarrays to study host-microbe interactions. Emerg Infect Dis 6:513-525
9. De Groot AS, Jesdale BM, Szu E, Schafer JR, Chicz RM, Deocampo G 1997 An interactive website providing major histocompatibility ligand predictions: application to HIV research. AIDS Res Hum Retroviruses 13:529-531
10. De Groot AS, Bosma A, Chinai M et al 2001 From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 19:4385-4395
11. De Groot AS, Sbai H, Saint-Aubin C, McMurry JA, Martin W 2002 Immuno-informatics: mining genomes for vaccine components. Immunol Cell Biol 80:255-269
12. De Groot AS, Rayner J, Martin W 2003 Modelling the immunogenicity of therapeutic proteins using T cell epitope mapping. Dev Biol (Basel) 112:71-80
13. Dhiman N, Bonilla R, O'Kane DJ, Poland GA 2001 Gene expression microarrays: a 21st century tool for directed vaccine design. Vaccine 20:22-30
14. Erickson AL, Walker CM 1993 Class I major histocompatibility complex-restricted cytotoxic T cell responses to vaccinia virus in humans. J Gen Virol 74:751-754
15. Falquet L, Pagni M, Bucher P et al 2002 The PROSITE database, its status in 2002. Nucleic Acids Res 30:235-238
16. Fleischmann RD, Adams MD, White O et al 1995 Whole genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269:496-512
17. Fraser CM, Gocayne JD, White O et al 1995 The minimal gene complement of Mycoplasma genitalium. Science 270:397-403
18. Godkin AJ, Smith KJ, Willis A et al 2001 Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions. J Immunol 166:6720-6727
19. Grossman Z, Paul WE 2001 Autoreactivity, dynamic tuning and selectivity. Curr Opin Immunol 13:687-698
20. Hanke T, Schneider J, Gilbert SC, Hill AVS, McMichael A 1998 DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 16:426-435
21. Holzhutter HG, Frommel C, Kloetzel PM 1999 A theoretical approach towards the identification of cleavage determining amino acid motifs of the 20S proteasome. J Mol Biol 286:1251-1265
22. Ishioka GY, Fikes J, Hermanson G et al 1999 Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol 162:3915-3925
23. Ito N, Kakemizu M, Ito KA et al 2001 A comparison of complete genome sequences of the attenuated RC-HL strain of rabies virus used for production of animal vaccine in Japan, and the parental Nishigahara strain. Microbiol Immunol 45:51-58
24. Jin X, Roberts CG, Nixon DF et al 2000 Identification of subdominant cytotoxic T lymphocyte epitopes encoded by autologous HIV type 1 sequences, using dendritic cell stimulation and computer-driven algorithm. AIDS Res Hum Retroviruses 16:67-76
25. Johnston SA, Barry MA 1997 Genetic to genomic vaccination. Vaccine 15:808-809
26. Le AX, Bernhard EJ, Holterman MJ et al 1989 Cytotoxic T cell responses in HLA-A2.1 transgenic mice. Recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element. J Immunol 142:1366-1371
27. Li Z, Howard A, Kelley C, Delogu G, Collins F, Morris S 1999 Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun 67:4780-4786
28. Lieberman J, Frankel FR 2002 Engineered Listeria monocytogenes as an AIDS vaccine. Vaccine 20:2007-2010
29. Livingston B, Crimi C, Newman M et al 2002 A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol 168:5499-5506
30. Lowe DC, Savidge TC, Pickard D et al 1999 Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA, aroC, and htrA. Infect Immun 67:700-707
31. Malin AS, Huygen K, Content J et al 2000 Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85. Microbes Infect 2:1677-1685
32. Man S, Newberg MH, Crotzer VL et al 1995 Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. Int Immunol 7:597-605
33. Menne KM, Hermjakob H, Apweiler RA 2000 Comparison of signal sequence prediction methods using a test set of signal peptides. Bioinformatics 16:741-742 (see also SignalP V1.1 World Wide Web Prediction Server, Centre for Biological Sequence Analysis, Department of Biotechnology, The Technical University of Denmark at http://www.cbs.dtu.dk/services/SignalP)
34. Morris S, Kelley C, Howard A, Li Z, Collins F 2000 The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine 18:2155-2163
35. Rodriguez F, Whitton JL 2000 Enhancing DNA immunization. Virology 268:233-238
36. Schafer JR, Jesdale BM, George JA, Kouttab NM, De Groot AS 1998 Prediction of well-conserved HIV-1 ligands using a Matrix-based algorithm, EpiMatrix. Vaccine 16:1880-1884
37. Schena M, Shalon D, Davis RW, Brown PO 1995 Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270:467-470
38. Seder RA, Hill AV 2000 Vaccines against intracellular infections requiring cellular immunity. Nature 406:793-798
39. Sharpe S, Fooks A, Lee J, Hayes K, Clegg C, Cranage M 2002 Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses. Virology 293:210-216
40. Shirai M, Arichi T, Nishioka M et al 1995 CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J Immunol 154:2733-2742
41. Stephenson JR 2001 Genetically modified viruses: vaccines by design. Curr Pharm Biotechnol 2:47-76
42. Sturniolo T, Bono E, Ding J et al 1999 Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotech 17:555-561
43. Suhan ML, Hovde CJ 1998 Disruption of an internal membrane-spanning region in Shiga toxin 1 reduces cytotoxicity. Infect Immun 66:5252-5259 (see also TMpred, European Molecular Biology network at http://www.ch.embnet.org/ software/TMPRED_form.html)
44. Tatusov RL, Mushegian AR, Bork P at al 1996 Metabolism and evolution of Haemophilus influenzae deduced from a whole-genome comparison with Escherichia coli. Curr Biol 6:279-291
45. Thomson SA, Khanna R, Gardner J et al 1995 Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ T cells: implications for vaccine design. Proc Natl Acad Sci USA 92:5845-5849
46. Thomson SA, Burrows SR, Misko IS, Moss DJ, Coupar, BE, Khanna R 1998 Targeting a polyepitope protein incorporating multiple class-II restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD8+ cytotoxic T lymphocytes: a novel approach to vaccine design. J Virol 72:2246-2252
47. Tine JA, Lanar DE, Smith DM et al 1996 NYVAC Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun 64:3833-3844
48. Velders MP, Weijzen S, Eiben GL et al 2001 Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 166:5366-5373
49. Whitton JL, Sheng N, Oldstone MB, McKee TA 1993 A "string-of- beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol 67:348-352
50. Yu K, Petrovsky N, Schönbach C, Koh JY, Brusic V 2002 Methods for prediction of peptide binding to MHC molecules: a comparative study. Mol Med 8:137-148
51. Zhang C, Anderson A, DeLisi C 1998 Structural principles that govern the peptide-binding motifs of class I MHC molecules. J Mol Biol 281:929-947